問卷

TPIDB > Search Result > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of General Internal Medicine

Division of Hematology & Oncology

Division of Thoracic Medicine

Division of Infectious Disease

National Taiwan University Hospital Hsin-Chu Branch (在職)

Division of Thoracic Medicine

Division of General Internal Medicine

National Taiwan University Cancer Center

Division of General Internal Medicine

更新時間:2025-03-04

余忠仁Yu, Chong-Jen
  • Principal Investigator
  • Clinical Trial Experience (year) -24 years -4 個月

篩選

List

358Cases

2025-11-14 - 2029-06-30

Phase I

Not yet recruiting
A Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of IDE892 as Monotherapy and Combination Therapy in Participants With MTAP-Deleted Advanced Solid Tumors
  • Condition/Disease

    NSCLC Adenocarcinoma

  • Test Drug

    錠劑 膠囊劑 錠劑

Participate Sites
4Sites

Recruiting4Sites

2016-07-01 - 2020-12-31

Others

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

邱昭華
Taipei Veterans General Hospital

Division of Hematology & Oncology

楊政達
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2018-04-02 - 2023-12-06

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2005-07-01 - 2008-07-01

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2013-12-01 - 2016-11-30

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2025-08-01 - 2031-12-31

Active
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2021-04-01 - 2033-02-28

Phase II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2024-06-01 - 2030-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Not yet recruiting6Sites

2020-01-01 - 2026-12-31

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2020-02-01 - 2025-12-10

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting5Sites

Terminated3Sites